Adagio Therapeutics, Inc. is a clinical-stage a biotechnology company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional pre-emergent coronaviruses. 

Biotechnology

Adagio Therapeutics

Mr. Hering joined Adagio from [Pfizer](/org/pfizer), where he most recently served as the global mRNA business lead, a business specifically created to optimize management of COVID-19 efforts, and led the launch of the first-ever COVID-19 vaccines worldwide.

David Hering is a seasoned life sciences leader who offers more than 25 years of experience creating and growing value for companies within the pharmaceutical and life sciences industry. Mr. Hering has spent much of his career leading functions within vaccine franchises at some of the top pharmaceutical companies. Prior to his most recent role at [Pfizer](/org/pfizer), Mr. Hering was president, North America at [Pfizer](/org/pfizer), where he led a 700-person organization across a portfolio of vaccine products in COVID-19 and meningococcal and pneumococcal diseases. Before [Pfizer](/org/pfizer), he held a number of roles of increasing responsibility at Novartis Vaccines, most recently as head of North America where he led an organization responsible for a portfolio of four vaccine products in meningitis and travel. Earlier, he was a consultant for Keystone Strategy, advising clients within the biotech industry, and held manufacturing-focused roles at Merck & Co., Inc. Mr. Hering holds an MBA from [Harvard Business School](/org/harvard-business-school) and B.S. in operations research and industrial engineering from [Cornell University](/org/cornell-university).

David Hering

Michael Wyzga is the president of MSW Consulting, Inc., a private company focused on strategic biotechnology consulting, a position he has held since November 2013. Prior to that, he served as president, chief executive officer and a member of the board of directors of Radius Health, Inc. From 1993 to 2011, Mr. Wyzga served in various senior management positions at Genzyme Corporation, including as executive vice president, finance and as chief financial officer. During his time with Genzyme, Mr. Wyzga played key roles in the successful development and commercialization of a number of important therapies, including Cerezyme for Gauche disease, Fabrazyme for Fabry’s disease, Renagel for use in the treatment of dialysis patients and Campath for chronic lymphocytic leukemia. Mr. Wyzga has served on a number of public company boards, including at Mereo BioPharma Group plc, OncoMed Pharmaceuticals, Inc., X4 Pharmaceuticals, GenSight Biologics, LogicBio Therapeutics, Akebia Therapeutics, Inc., Idenix Pharmaceuticals, Inc., Prosensa Holding B.V. Mr. Wyzga received an MBA from Providence College and a B.S. from Suffolk University.

Michael Wyzga

Laura Walker is the Co-Founder and Chief Scientific Officer at [Adagio Therapeutics](/org/adagio-therapeutics). Laura was previously a Group Leader at [Adimab](/org/adimab), LLC from May 2012 to March 2022. At [Adimab](/org/adimab), their team focused on the discovery and optimization of antibodies using yeast library technology and single B cell cloning.

Before their work at [Adimab](/org/adimab), Laura was a Graduate Student at The [Scripps Research](/org/scripps-research-institute) Institute from September 2007 to August 2011, where they isolated and characterized broadly neutralizing antibodies against HIV.

Laura’s experience in antibody research and development makes their uniquely qualified to lead [Adagio Therapeutics](/org/adagio-therapeutics) in their mission to develop innovative therapies for patients with autoimmune diseases.

Laura Walker has a Ph.D. in Microbiology and Immunology from [Scripps Research](/org/scripps-research-institute) and a BS in biochemistry from University of Wisconsin-Madison.

They are on a team with Ed Campanaro - SVP, Clinical Operations, David Hering - COO, and Eric Kimble - Chief Commercial Officer. Their manager is Tillman Gerngross, Co-Founder & CEO.

Laura Walker

Eric Kimble is the current Chief Commercial Officer at [Adagio Therapeutics](/org/adagio-therapeutics). Prior to this, they served as the Chief Commercial Officer at [Entasis Therapeutics](/org/entasis-therapeutics) from April 2019 to September 2020. Before their work in the commercial sector, Eric was an English teacher and baseball coach at St. John's Preparatory School from September 2013 to March 2019. Eric has also worked as a consultant for start-up antibiotic companies and as a Biotech Consultant for six pre- and peri-launch antibiotic startup companies. Prior to their consulting work, Eric held various positions at Cubist Pharmaceuticals from June 2004 to August 2013, including VP of Sales and Marketing, VP of Program Management, and Marketing Brand Leader. Eric Kimble has also worked as a Marketing Director at [Biogen](/org/biogen) from December 1999 to April 2004 and as a Product Manager at Merck & Co., Inc from August 1994 to December 1999.

Eric Kimble's educational career includes an MBA from [Harvard Business School](/org/harvard-business-school) and a A.B. from [Brown University](/org/brown-university), where they double majored in English Literature / Business Economics. Eric also attended high school at St. John's Prep and Loyola High School.

Some of their coworkers include Ed Campanaro - SVP, Clinical Operations, Ellie Hershberger - Chief Development Officer, and Becky Dabora - Chief Technology & Manufacturing Officer. Eric Kimble reports to Tillman Gerngross, Co-Founder & CEO.

Eric Kimble

Jane Pritchett Henderson is the current Chief Financial Officer at [Adagio Therapeutics](/org/adagio-therapeutics). Jane has also held this position at Akero Therapeutics, [Iveric Bio](/org/iveric-bio), and Voyager Therapeutics, Inc. Henderson has been a Board of Directors Member and Chair of the Audit Committee at [Sesen Bio](/org/sesen-bio) since October 2013. Prior to that, they were the Vice President of Business Development at ISTA Pharmaceuticals from June 2010 to June 2012. Henderson has also served as the Executive Vice President, Chief Financial Officer, and Head of Business Development at Axerion Therapeutics, Inc.

Jane Pritchett Henderson has a Bachelor of Science in Psychology from [Duke University](/org/duke-university).

Jane Pritchett Henderson works with Ellie Hershberger - Chief Development Officer, Eric Kimble - Chief Commercial Officer, and David Hering - COO. Jane Pritchett Henderson reports to Tillman Gerngross, Co-Founder & CEO.

Jane Pritchett Henderson

Tom Heyman has a long-standing track record in the biopharmaceutical industry, with particular experience in business development and venture capital. He most recently served as president of JJDC, the venture capital group within Johnson & Johnson, where he managed approximately $1.5 billion of capital and oversaw investments in over 120 companies. Prior to his role at JJDC, Mr. Heyman spent 23 years leading business development for Johnson & Johnson’s pharmaceutical group, Janssen, where he was involved in hundreds of licensing and M&A transactions. Under his leadership, major licensing transactions were executed for products like Levaquin, Aciphex, Incivo, Olysio, Velcade, Invokana, Imbruvica, Xarelto and Darzalex, many of which have achieved sales of over $1 billion annually. Also, during his tenure, he led Janssen Belgium through a significant reorganization and implemented a new strategic plan for the site with a major emphasis on external innovation and value creation. Mr. Heyman graduated as Master of Law from the K.U. Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in business management at the University of Antwerp in Belgium.

Tom Heyman

Anand Shah, M.D., is a U.S. health policy leader who recently served as the deputy commissioner for medical and scientific affairs at the FDA. Dr. Shah led medical and scientific policy development for high priority programs including Advanced Manufacturing, the Coronavirus Treatment Acceleration Program, COVID-19 vaccine development, and decentralized clinical trials. Under his leadership, FDA initiated the Pandemic Recovery and Preparedness Plan (PREPP) to strengthen the response to the COVID-19 pandemic and resiliency for future public health emergencies. Dr. Shah represented FDA with top-level policy makers of the White House and Cabinet, Congress, and state and local governments. He previously served in senior leadership at the Centers for Medicare & Medicaid Services, both as senior medical advisor and chief medical officer of the Center for Medicare & Medicaid Innovation. Dr. Shah was chief resident during his radiation oncology residency at Columbia University. He concurrently earned his M.D. from the University of Pennsylvania and an M.P.H. in health care management and policy from the Harvard School of Public Health. Dr. Shah has an economics degree from Duke University.

Adagio Therapeutics

Org chart

Teams

CEO and Executive Team

Leadership Team

Board of Directors

Founding Team

Discover similar companies